Maternal care for anti-D [Rh] antibodies, first trimester (fetus 4)
ICD-10 O36.0114 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, first trimester (fetus 4).
O36.0114 refers to maternal care for a pregnancy complicated by the presence of anti-D (Rh) antibodies during the first trimester, specifically for the fourth fetus. This condition arises when an Rh-negative mother carries an Rh-positive fetus, leading to the potential for hemolytic disease of the newborn (HDN) if not monitored and managed appropriately. The presence of these antibodies can cause fetal complications such as growth restriction, fetal distress, and even intrauterine fetal demise if the condition is severe and left untreated. Regular monitoring through ultrasound and maternal blood tests is essential to assess fetal well-being and growth patterns. Management may include additional interventions such as intrauterine transfusions or early delivery if fetal distress is detected. The complexity of care increases with the number of fetuses and the presence of other maternal or fetal complications, necessitating a multidisciplinary approach to ensure optimal outcomes for both mother and fetus.
Detailed records of maternal blood tests, ultrasound findings, and treatment plans are essential.
Management of Rh incompatibility in a pregnant patient with a history of anti-D antibodies.
Ensure accurate tracking of fetal growth and maternal health to prevent complications.
Comprehensive documentation of high-risk factors, including maternal history and fetal assessments.
Monitoring and managing pregnancies complicated by Rh sensitization and its effects on fetal health.
Collaboration with other specialists is crucial for managing complex cases.
Used for monitoring fetal growth and well-being in pregnancies complicated by anti-D antibodies.
Document the reason for the ultrasound and findings related to fetal health.
Obstetricians should ensure that ultrasound reports are detailed and correlate with maternal conditions.
Anti-D antibodies can lead to serious fetal complications if the mother is Rh-negative and the fetus is Rh-positive. Monitoring and management are crucial to prevent hemolytic disease of the newborn.
